Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-04-07
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data ReviewTERN — Terns Pharmaceuticals Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$52.86+17.47%Market cap5.62B
- Latest Close
- $52.86
- 30-Day Move
- +17.5%
- Market Cap
- $5.6B
- Shares Outstanding
- 106,200,000
- P/B Ratio
- 1.36
- ROE
- -25.7%
Analyst consensus: Buy · 17 analysts
NASDAQ:TERNPharmaceuticals / PharmaceuticalsDelayed public snapshot
Terns Pharmaceuticals Inc
A read-only Alphactor snapshot forTerns Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$52.86
30-Day Move
+17.5%
Market Cap
$5.6B
Shares Outstanding
106,200,000
P/B Ratio
1.36
ROE
-25.7%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$52.86
+17.5%last 90 delayed daily bars
Market cap$5.6B
90D High
$53.19
90D Low
$33.43
Avg Volume
4,922,136
What stands out
Net margin is -5016.0%, useful for comparing TERN against peers in Pharmaceuticals.
TERN is up 17.5% over the last 30 trading days shown on this page.
Latest operating income is $-110M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
29.2%
Fundamentals snapshot
Latest Close
$52.86
30-Day Move
+17.5%
Market Cap
$5.6B
Shares Outstanding
106,200,000
P/B Ratio
1.36
ROE
-25.7%
ROA
-24.4%
Operating Margin
-4986.0%
Net Margin
-5016.0%
Debt / Equity
0
Current Ratio
23.14
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-110M
Net Income
$-96M
Gross Margin
--
Net Margin
-501600.0%
Current Ratio
23.14
Debt / Equity
0.00
Quality snapshot
Altman Z
181.88
Safe
Piotroski
4
Moderate (4-6)
Cash Conversion
0.85x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-62M | $-60M | $-49M |
| 2023-12-31 | $0 | $-103M | $-90M | $-67M |
| 2024-12-31 | $0 | $-102M | $-89M | $-70M |
| 2025-12-31 | $0 | $-110M | $-96M | $-82M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-04-07
What's Going On With Merck Stock Tuesday?Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/investing.ico', homepage_url='https://www.investing.com/', logo_url='https://s3.massive.com/public/assets/news/logos/investing.png', name='Investing.com')•2026-04-02
Merck Just Made a Big Bet on a New Cancer Growth EnginePublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-04-01
Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody DrugsPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-03-25
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: AnalystAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$186,595.34
Sell Value
$7M
Buys
6
Sells
14
Buy Value
$186,595.34
Sell Value
$7M
Buy/Sell Ratio
0.43x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | Kuriakose Emil | Sell | 942 | $52.75 |
| 2026-03-16 | Burroughs Amy L. | M | 14,583 | $0.00 |
| 2026-03-16 | Burroughs Amy L. | Sell | 2,770 | $47.30 |
| 2026-03-16 | Burroughs Amy L. | Sell | 11,813 | $46.57 |
| 2026-03-16 | Burroughs Amy L. | M | 14,583 | $4.64 |
| 2026-02-17 | Burroughs Amy L. | M | 14,583 | $0.00 |
| 2026-02-17 | Burroughs Amy L. | Sell | 4,083 | $39.80 |
| 2026-02-17 | Burroughs Amy L. | Sell | 8,159 | $39.22 |
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-11-14
--
--
Vanguard Group
Filed 2026-01-29
$223M
+21.1%
Citadel Advisors
Filed 2026-02-17
$128M
--
Geode Capital Management
Filed 2026-02-09
$85M
+22.3%
D.E. Shaw
Filed 2026-02-17
$47M
--
Goldman Sachs
Filed 2026-02-10
$43M
+94.4%
FMR LLC (Fidelity)
Filed 2026-02-17
$41M
+1601.5%
Marshall Wace
Filed 2026-02-13
$35M
--
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
3.82
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
17
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.